Ryan Haumschild, PharmD, MS, MBA

Video content above is prompted by the following: Ungar: The Severity of Alopecia Tool (SALT) is a validated tool utilized to assess the clinical severity of alopecia with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp […]

Video content above is prompted by the following: Ungar: The Severity of Alopecia Tool (SALT) is a validated tool utilized to assess the clinical severity of alopecia with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp

Video content above is prompted by the following: McMichael: What are the hallmark symptoms of AA, and how can it fluctuate with time making this a relapsing or remitting inflammatory disease? Source link Ryan Haumschild, PharmD, MS, MBA

Video content above is prompted by the following: Friedland: In addition to dermatologic symptoms, there are also psychological effects seen from ongoing or recurrent hair loss. How can may this these impact the mental health of the patient? Friedland: Are

Video content above is prompted by the following: Ungar: What is the epidemiology of AA, and can you describe the different forms of AA that you see in your practice? Is there a population in which AA occurs more frequently

Video content above is prompted by the following: Mostaghimi: What are the concurrent comorbidities commonly seen in patients with AA? How do they contribute to the burden of disease? How do these affect your management plan? Source link Ryan Haumschild,

Video content above is prompted by the following: Describe the pathophysiology of alopecia areata (AA) and what makes it a chronic, autoimmune disease?. a. Describe the role of inflammation in AA. Source link Ryan Haumschild, PharmD, MS, MBA

We’ve discussed first-line therapies and a newly approved therapy tarlatamab.  Beyond first-line therapies, what options exist for patients, and what clinical trials are you excited about? What are some of the therapies being researched for small cell lung cancer (SCLC)

Panelists discuss how health care providers and payers can collaborate more effectively to optimize lupus nephritis care. Source link Ryan Haumschild, PharmD, MS, MBA

We’ve discussed first-line therapies and a newly approved therapy tarlatamab.  Beyond first-line therapies, what options exist for patients, and what clinical trials are you excited about? What are some of the therapies being researched for small cell lung cancer (SCLC)